AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- Computerized Thermal Imaging, Inc., (CTI, COIB) announced that it has received a Medical Device License from Health Canada to market its Breast Cancer Imaging System (BCS2100) in Canada.
The BCS2100 uses infrared thermal imaging (IR) as an adjunct device to assist doctors in the early detection and discrimination of breast cancer. The process is designed to be quick, painless, non-invasive, and requires no patient exposure to radiation, breast compression, or electrical current.
J.R. Keyserlingk, medical directors of VilleMarie Breast and Oncology Center in Montreal stated that, "Integrating IR imaging into the first-line strategy for the detection of breast cancer can increase the sensitivity at this crucial stage by providing an early warning of an abnormality that in some cases is not evident in other components. Combining IR imaging and mammography in an IR-assisted mammography strategy is particularly appealing in the current era of increased emphasis on screening by imaging and less reliance on palpation as tumor size further decreases."
"I am pleased that CTI has received a Medical Device License to market the BCS 2100 in Canada," said Richard Secord, CTI chairman and CEO. "CTI is in business to improve the quality of life through the development and deployment of thermal imaging and associated technologies. Our goal is to provide radiologists additional information to assist them in better determining the need for surgical biopsy."
As part of the Medical Device License, CTI was required to be certified to the ...
Source: HighBeam Research, License granted to market breast imaging system in Canada.